Right Heart Pressure Increases after Acute Increases in Ambient Particulate Concentration

David Q. Rich,1,2 Ronald S. Freudenberger,3,4 Pamela Ohman-Strickland,1,2 Yong Cho,5 and Howard M. Kipen2,3

1School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA; 2Environmental and Occupational Health Sciences Institute, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School and Rutgers University, Piscataway, New Jersey, USA; 3University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick/Piscataway, New Jersey, USA; 4Center for Advanced Heart Failure, Lehigh Valley Hospital and Health Network, Allentown, Pennsylvania, USA; 5Medtronic Inc., Minneapolis, Minnesota, USA

OBJECTIVES: We explored the association between acute changes in daily mean pulmonary artery (PA) and right ventricular (RV) pressures and concentrations of ambient fine particulate matter [PM with aerodynamic diameter ≤ 2.5 μm (PM2.5)] as an explanation for previous associations between congestive heart failure (HF) hospital admissions and PM.

MATERIALS AND METHODS: In the Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure (COMPASS-HF) trial, to see whether management of ambulatory HF could be improved by providing continuous right heart pressure monitoring to physicians, the Chronicle Implantable Hemodynamic Monitor (Medtronic, Inc., Minneapolis, MN, USA) continuously measured multiple right heart hemodynamic parameters, heart rate, and activity trends in subjects with moderate/severe HF. Using these trial data, we calculated daily mean pressures, using only those time intervals where the subject was not physically active (n = 5,807 person-days; n = 11 subjects). We then studied the association between mean daily PA/RV pressures and mean ambient PM2.5 concentrations on the same day and previous 6 days.

RESULTS: Each 11.62-µg/m3 increase in same-day mean PM2.5 concentration was associated with small but significant increases in estimated PA diastolic pressure [0.19 mmHg; 95% confidence interval (CI), 0.05–0.33] and RV diastolic pressure [0.23 mmHg; 95% CI, 0.11–0.34]. Although we saw considerable differences in the magnitude of response by COMPASS-HF randomization group (total data access for physicians vs. blocked clinician access), season, left ventricular ejection fraction, and obesity, these effects were not significantly different.

CONCLUSIONS: These pilot study findings provide a potential mechanism for previous findings of increased risk of HF associated with ambient PM. However, because of the small number of subjects, a larger study is needed for confirmation.

KEY WORDS: air pollution, diastolic, heart, pressure, pulmonary artery, right ventricle. Environ Health Perspect 116:1167–1171 (2008). doi:10.1289/ehp.11230 available via http://dx.doi.org/ [Online 28 May 2008]

Increased incidence of specific acute cardiovascular outcomes, including myocardial infarction, ventricular arrhythmia, episodes of atrial fibrillation, ischemic stroke, and heart failure (HF), have been reported to occur immediately after as little as 1–2 hr of increased particulate matter (PM) concentration (Peters et al. 2001; Rich et al. 2006b), as well as 1–2 days later (Burnett et al. 1999; D’Ippoliti et al. 2003; Morris and Naumova 1998; Morris et al. 1995; Peters et al. 2000, 2005; Rich et al. 2005, 2006a; Schwartz and Morris 1995; Symons et al. 2006; Wellenius et al. 2005a, 2005b, 2006; Wong et al. 1999; Zanobetti and Schwartz 2005). However, not all studies have reported these acute to subacute responses (Levy et al. 2001; Rich et al. 2004; Sullivan et al. 2005; Vedal et al. 2004). Recent epidemiologic, animal, and controlled human exposure studies have suggested that PM air pollution may elicit changes in subclinical indices, such as autonomic function, inflammation, endothelial dysfunction, and thrombotic tendency within hours after air pollution exposures, which may contribute to the increased incidence of cardiovascular disease observed (Brook et al. 2002; Gold et al. 2000; Liao et al. 1999; Magari et al. 2001, 2002; Mills et al. 2005, 2007; Nemmar et al. 2002, 2003; Riediker et al. 2004; Ruckerl et al. 2006; Tornqvist et al. 2007; Tunnifilie et al. 2001; Wellenius et al. 2003).

Wellenius et al. (2005a) reported small but statistically significant increases in the risk of HF hospital admissions associated with increases in same-day PM10 and nitrogen dioxide concentration in Pittsburgh, Pennsylvania. In a later multicity study, these same investigators reported a 0.72% [95% confidence interval (CI), 0.35–1.10%] increase in risk of HF admission for each 10-µg/m3 increase in same-day ambient PM10 concentration (Wellenius et al. 2006). These Medicare database admission studies demonstrated acute cardiovascular responses to air pollution that require an exploration of possible physiologic correlates both for verification and for clues as to mechanism. We hypothesized that hospital admissions for decmompensation of HF that were triggered by air pollution would be associated with more frequent subclinical increases in pulmonary arterial (PA) diastolic and right ventricular (RV) pressures. Such pressure increases could ultimately lead to emergency department/hospital admission when individuals are vulnerable due to the presence of other established HF exacerbation triggers (e.g., volume overload, electrolyte status, decreased oxygenation, rhythm disturbance, exertion, decreased myocardial contractility, suboptimal medical therapy). If PM has a causal role in HF admissions because of acute pressure increases, then direct passive measurement of these specific pressures should be a much more sensitive and upstream measure of stress on the cardiopulmonary system than hospital admissions for HF, which presumably depend on a confluence of exacerbating factors.

Therefore, we coupled passively monitored data of continuous PA diastolic and RV pressure data in HF patients implanted with the Chronicle Implantable Hemodynamic Monitor (Medtronic, Inc., Minneapolis, MN) and ambient fine PM (aerodynamic diameter ≤ 2.5 μm (PM2.5)) measurements made at monitoring stations throughout New Jersey. In this pilot study to investigate the feasibility of such an approach to examine mechanisms underlying previously reported associations between air pollution and HF, we examined the association between daily mean PM2.5 concentrations and daily mean PA and RV pressures.

Address correspondence to D.Q. Rich, Department of Epidemiology, University of Medicine and Dentistry of New Jersey, School of Public Health, 683 Hoes Lane West, Piscataway, NJ 08854 USA. Telephone: (732) 235-4664. Fax: (732) 235-5418. E-mail: richea@umdnj.edu

This research was supported, in part, by the National Institute of Environmental Health Sciences (NIEHS)—sponsored University of Medicine and Dentistry of New Jersey’s Center for Environmental Exposures and Disease, grant NIEHS P30ES05022, U.S. Environmental Protection Agency (EPA) Star Grant R832144, and American Heart Association (AHA) grant 0735287N.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, U.S. EPA, or AHA.

R.S.F. has previously received grant support from and served as a consultant to Medtronic, Inc. Y.C. is an employee of Medtronic, Inc. The remaining authors declare they have no competing financial interests.

Received 3 January 2008; accepted 23 May 2008.
Materials and Methods

Study population and outcomes. We studied class III HF patients who were participating in the COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) trial and were implanted with the Chronicle at either Robert Wood Johnson University Hospital in New Brunswick, New Jersey, or Beth Israel Medical Center in Newark, New Jersey (n = 13 subjects). In this trial, the Chronicle continuously measured and stored intracardiac pressure, body temperature, physical activity, and heart rate. This device has been described in detail previously (Bourge et al. 2008). Briefly, the device includes a programmable unit similar to the pulse generator of a pacemaker, and a transvenous lead with a sensor near its tip to measure intracardiac pressures. The device is positioned subcutaneously in the pectoral area. The lead is placed transvenously with its tip located in the RV outflow tract or high septum. Approximately every 8 min, the device stores the medians of several pressure metrics, including estimated PA diastolic pressure (ePAD), RV diastolic pressure, RV systolic pressure, mean PA pressure (MPAP), physical activity, and heart rate (beats per minute). ePAD is defined as the RV pressure at the time of pulmonary valve opening and is correlated (r = 0.84) with actual PA pressure (Magalski et al. 2002; Ohlsson et al. 1995; Zile and Brutsaert 2002). Physical activity level was measured by an accelerometer in the chest wall device. Any physical activity sensed by the accelerometer is measured and averaged over the programmed storage interval (i.e., 8 min). A physical activity of 0 means that the sensor did not detect any activity during that interval.

Each week, these measurements were transmitted by patients via telephone line and subsequently downloaded to each patient’s cardiologist using the Internet. As part of the COMPASS-HF trial, subjects were randomized to either “total clinician access,” which meant the cardiologist could view these pressure data and could monitor the subject only during regularly scheduled clinic visits (i.e., the normal standard of care). Details of this trial have been published previously (Bourge et al. 2008). A barometric pressure monitor (Chronicle Tracker, Medtronic, Inc.) worn by the patient also made continuous measurements and stored values for the same time intervals as the heart pressure readings. As part of the COMPASS-HF trial, ejection fraction was obtained by standard clinical echocardiography. Heart failure etiology was based on clinical criteria. If there was known coronary artery disease or history of myocardial infarction, patients were categorized as ischemic. Patients without these conditions were categorized as non ischemic.

Of the original 13 study subjects implanted with the Chronicle, we excluded one patient who lived in New York because we could not match a New Jersey air pollution monitor to that person. We also excluded a second subject who died of septic shock 24 days after device implantation, leaving 11 subjects for analysis. For each subject, we included all pressure data from the date of implant through the date of death or last data transmission before 11 January 2007 (range, 358–1,090 days; median, 846 days [2.32 years]). For our primary analysis examining changes in daily pressure and daily PM2.5 concentration, we excluded all intervals where the subject’s physical activity was > 0 and then calculated mean PA and RV pressures for each day of observation, leaving n = 5,807 person-days (n = 11 subjects) for analysis. The University of Medicine and Dentistry of New Jersey Institutional Review Board (New Brunswick and Piscataway campuses) approved this study.

PM and weather measurements. PM2.5 was measured continuously in New Brunswick, Camden, Elizabeth, Jersey City, and Rahway, New Jersey, during the study period by the New Jersey Department of Environmental Protection (Trenton, NJ) using a tapered element oscillating microbalance. We retrieved hourly concentrations at these stations from the U.S. Environmental Protection Agency (EPA) website (U.S. EPA 2007). For each subject, we calculated the distance between each PM2.5 monitor and the subject’s residence, assigning PM2.5 measurements from the closest monitor to their residence. We assigned all subjects PM2.5 measurements from either the New Brunswick or Elizabeth monitoring sites (median distance, 13.4 km; range, 7.0–34.2 km).

Temperature and dew point were measured hourly at the Newark, Caldwell, Somerset, and Trenton airports during the study period. We used the airport monitor closest to each subject’s residence to provide the weather observations for that subject during the study period. For each day, we calculated apparent temperature (Kalkstein and Valimont 1986; O’Neill et al. 2007; Steadman 1979; Zanobetti and Schwartz 2005) as a measure of each subject’s perceived air temperature given the humidity [apparent temperature = −2.653 × (0.994 × air temperature) + (0.0153 × dewpoint)] and used these values in all analyses.

Statistical analysis. We used a two-step modeling process to estimate the change in daily mean ePAD associated with each incremental increase in same-day (i.e., lag 0) mean PM2.5 concentration. In the first step, each subject appeared to have different long-term patterns in ePAD during the follow-up period (data not shown). Therefore, we removed long-term trends in ePAD separately for each person via spline-based nonparametric regression. We regressed a natural cubic spline (3 degrees of freedom) of time against ePAD and obtained residuals from this model to be used as the outcome in the second step of the analysis. We found that higher degrees of freedom were not necessary for modeling the long-term trends and did not substantially alter the results in the second step of the analysis (data not shown). In the second step, focusing on average short-term pressure changes associated with same-day PM2.5 concentration, we used a repeated-measures model with these residuals as the response, combining all subjects’ data into a single model. We regressed fixed factors of same-day PM2.5 concentration, day of week, and month, as well as quadratic effects of apparent temperature and barometric pressure, against these residuals.

Table 1. Characteristics of study population (n = 11).

| ID no. | Sex | Race | Height (m) | Weight (kg) | BMI (kg/m²) | Age at implant (years) | HF etiology | Heart rate at implant (bpm) | LVEF at implant | Other implanted device |
|--------|-----|------|------------|-------------|-------------|------------------------|-------------|-----------------------------|----------------|-----------------------|
| 01     | Female | White | 1.60       | 78.9         | 30.8        | 60                     | Ischemic   | 76                          | 65             | None                  |
| 02     | Female | White | 1.68       | 67.1         | 23.9        | 57                     | Nonischemic| 71                          | 20             | None                  |
| 03     | Female | White | 1.60       | 97.5         | 38.1        | 33                     | Nonischemic| 82                          | 15             | ICD                   |
| 04     | Female | Hispanic | 1.65      | 92.1         | 33.8        | 42                     | Nonischemic| 84                          | 40             | None                  |
| 05     | Female | Black  | 1.55       | 74.8         | 31.2        | 49                     | Nonischemic| 48                          | 45             | None                  |
| 06     | Male   | White  | 1.83       | 86.0         | 26.4        | 65                     | Nonischemic| 76                          | 20             | Bi-V ICD              |
| 07     | Male   | White  | 1.70       | 92.1         | 31.8        | 67                     | Ischemic   | 80                          | 40             | ICD                   |
| 08     | Male   | White  | 1.75       | 117.9        | 38.4        | 61                     | Nonischemic| 72                          | 20             | Bi-V ICD              |
| 09     | Female | Black  | 1.65       | 130.6        | 47.9        | 25                     | Nonischemic| 94                          | 15             | ICD                   |
| 10     | Male   | White  | 1.73       | 73.9         | 24.8        | 53                     | Ischemic   | 84                          | 35             | ICD                   |
| 11     | Male   | White  | 1.75       | 100.2        | 32.6        | 68                     | Ischemic   | 56                          | 22             | ICD                   |
using a first-order autocorrelation structure, such that we modeled measurements separated by $d$ days to have a correlation of $\rho^d$, where $\rho$ represents the correlation between measurements from 2 successive days. We then repeated this procedure to examine separately the changes in daily RV diastolic pressure, RV systolic pressure, and MPAP associated with each 11.62 μg/m$^3$ increase (the interquartile range observed during the study period) in same-day mean PM$_{2.5}$ concentration. Relative to compound symmetry, we found the first-order autocorrelation structure provided a better fit for the data as determined by Akaike’s information criterion.

Next, to evaluate whether the assumption of a linear exposure response function was justified, we examined the concentration–response using quintiles of PM$_{2.5}$ and performed a test of trend. Last, to evaluate whether any association between daily right heart pressure and same-day PM$_{2.5}$ concentration was independent of previous days’ mean PM$_{2.5}$ concentrations, we repeated this two-stage modeling process including the mean PM$_{2.5}$ concentrations from lag days 0–6, rather than just lag 0, in the same model. For each analysis, we present the unit change in right heart pressure associated with each 11.62 μg/m$^3$ increase in PM$_{2.5}$ concentration, and its 95% CI.

We also evaluated effect modification of any pressure–PM$_{2.5}$ association by randomization group (total clinician access vs. blocked clinician access), left ventricular ejection fraction (LVEF) at implantation ($\geq$ 45% vs. < 45%), season (winter vs. summer), and BMI at implantation (< 30%, $\geq$ 30%), and antihyperlipidemia medications (n = 4), digoxin (n = 8), anticoagulants (n = 6), aspirin (n = 6), and antihyperlipidemia medications (n = 4).

We found significant increases in daily mean ePAD and RV diastolic pressure, and nonsignificant increases in daily mean RV systolic pressure and MPAP, associated with each 11.62-μg/m$^3$ increase in same-day mean PM$_{2.5}$ concentration, after adjusting for long-term time trends, calendar month, weekday, and apparent temperature (Table 2). Because we found larger, significant associations with ePAD and RV diastolic pressure, we restricted all further analyses to these pressure measurements.

Changes in RV diastolic pressure and ePAD generally increased with quintiles of PM$_{2.5}$ (Figure 1), and the tests for trend were statistically significant for both pressures (RV diastolic pressure, $p < 0.001$; ePAD, $p = 0.006$). When we included the mean PM$_{2.5}$ concentrations for lag days 1–6 in the same model, ePAD and RV diastolic pressure increases associated with each 11.62-μg/m$^3$ increase in same-day (lag 0) mean PM$_{2.5}$ concentration were not substantially attenuated and remained statistically significant (ePAD: 0.17 mmHg; 95% CI, 0.02–0.32; RV diastolic pressure: 0.23 mmHg; 95% CI, 0.10–0.35) (Figure 2).

We found no statistically significant effect modification of the PM$_{2.5}$–RV diastolic pressure association by access randomization group, LVEF at implantation, season, or BMI at implantation (Table 3). However, the unit change in RV diastolic pressure was largest for the blocked clinician access randomization group compared with the total clinician access group, subjects with LVEF $\geq$ 45% at implantation compared with subjects with LVEF < 45%, winter versus summer person-days, and obese subjects compared with nonobese subjects (Table 3).

Results

Subjects were predominantly white (73%), and obese (73% had BMI $\geq$ 30) and ranged in age from 25 to 68 years (median, 57 years). All but two subjects had LVEFs < 45% at Chronicle implantation, and seven (64%) also had an implantable cardioverter defibrillator (ICD) or biventricular ICD (Bi-V ICD) (Table 1). All subjects ($n = 11$) were taking beta-blockers and diuretics during the study period, with lower but substantial proportions taking angiotensin converting enzyme inhibitors ($n = 9$), amiodarone ($n = 4$), digoxin ($n = 8$), anticoagulants ($n = 6$), aspirin ($n = 6$), and antihyperlipidemia medications ($n = 4$).

| Outcome | No. of person-days | Change in pressure (mmHg) | 95% CI | p-Value |
|---------|-------------------|---------------------------|--------|---------|
| ePAD    | 5,807             | 0.19                      | 0.05 to 0.33 | 0.01    |
| RV diastolic pressure | 5,807 | 0.23 | 0.11 to 0.34 | <0.001 | 0.23 |
| RV systolic pressure | 5,807 | 0.12 | -0.07 to 0.31 | <0.001 | 0.23 |
| MPAP    | 5,667             | 0.12                      | -0.05 to 0.28 | 0.16    |

Discussion

In a pilot study using continuous PA and RV pressures in 11 class III HF patients and ambient measurements of PM$_{2.5}$ at nearby monitoring stations, we observed small, but statistically significant increases in mean daily ePAD and RV diastolic pressure (0.19 and 0.23 mmHg, respectively) associated with each 11.62-μg/m$^3$ increase in mean PM$_{2.5}$ concentration on the same day. These increases were not attenuated when controlling for the previous 6 lag days of mean PM$_{2.5}$ concentration. Further, the concentration–response functions were generally linear. However, we found no statistically significant effect modification by access randomization group, LVEF at implantation, obesity, or season. These findings add mechanistic plausibility to previous studies’ reports of increased hospital admissions for HF associated with ambient PM concentrations in the previous few days (Burnett et al. 1999; Morris et al. 1995; Schwartz and Morris 1995; Symons et al. 2006; Wellenius et al. 2005a, 2006).

The observed pattern of lag day response (strongest effect on lag day 0, a negative effect on lag day 1–3, and little change in pressure for lag days 4–6) is a pattern similar to that observed by Wellenius et al. (2006). In their study of Medicare hospital admissions for HF, they reported a 0.72% increase in the risk of hospital admission for HF associated with each 10-μg/m$^3$ increase in PM$_{10}$ on lag day 0, a negative association on lag day 1, and no association on lag days 2 and 3.

Ambient PM may trigger pathophysiologic mechanisms by several means, which ultimately lead to acute exacerbation of HF. These include direct depressant effects on the...
myocardium secondary to ischemia (Pekkanen et al. 2002; Wellenius et al. 2003), arrhythmia (Rich et al. 2005, 2006a), PA vasoconstriction (observed in rodent models; Batalla et al. 2002), and reduced alveolar fluid clearance (Mutilu et al. 2006). These nonischemic mechanisms may be of particular importance because most of our subjects did not have an underlying ischemic mechanism for their HF (n = 7). The ultimate effect of any of those pathways would be an increase in right heart pressures, leading to hospitalization if it is amplified and prolonged without compensation or treatment. The pressure changes resulting in a hospitalization for HF are certainly much greater than those observed on average for these 11 subjects, perhaps between one and two orders of magnitude. One possible explanation for the muted pressure response to ambient PM2.5 in these 11 subjects is better management, with state-of-the-art medical therapy (a requirement of the COMPASS-HF trial), than that received by the population of Medicare patients examined by Wellenius et al. (2006). Thus, our lack of dramatic pressure changes does not negate the likelihood that the small changes we observed could trigger larger changes in an HF patient more particularly prone to decompensation. Ultimately, the small changes we observed and the limited number of subjects in our analysis suggest the need for further study in larger panels/cohorts to validate RV pressure increases as a mechanism for acute air pollution effects on HF exacerbations.

Although our study had strengths, including passive continuous monitoring of PA and RV pressures in moderate to severe HF patients, it also had several limitations. First, exposure misclassification was likely because we used ambient measurements of PM2.5 to approximate each subject’s exposure, rather than personal measurements. However, because this exposure error is likely nondifferential with respect to heart pressure measurements, our reported effect estimates are likely underestimated.

Second, it is possible that residual confounding by meteorology conditions or an unmeasured confounder may be responsible for the effects observed. However, that factor would have to both be correlated with daily mean PM2.5 concentrations measured at the monitoring stations and increases in daily mean PA and RV pressures in these 11 subjects. Thus, it seems unlikely that other meteorologic conditions not correlated with those included in our analysis (temperature, relative humidity, and barometric pressure) or other acutely time-varying, non-weather-related factors could explain the results observed.

Third, although we retained 5,807 person-days in our analysis, these were among only 11 subjects, resulting in reduced statistical power in our main analyses and even less power in our assessment of effect modification by subject specific characteristics (e.g., access randomization group, obesity, and LVEF at implantation) and season. However, although we found no statistically significant effect modification by these characteristics, there were considerable differences in the magnitude of response between each level of these characteristics (e.g., total clinician access vs. blocked clinician access, obese vs. nonobese, LVEF ≥ 45% vs. LVEF < 45%, winter vs. summer), suggesting that with a larger sample size these differences may have been statistically significant. The previously reported associations between obesity and susceptibility to air pollution (Chen et al. 2007; Zeka et al. 2006) as well as increased PM-related health effects in winter time (Becker et al. 2005) are consistent with our findings.

In this pilot study of the acute effects of ambient PM2.5 concentrations on a likely precursor of hospital admissions for HF exacerbation (PA and RV pressure increases), we demonstrated the feasibility of linking ambient air pollution data to continuously measured right heart pressures in HF patients. Further, we found significant increases in daily ePAD and RV diastolic pressure associated with increases in same-day ambient PM pollution concentrations. We have planned confirmation in a larger sample with more varied geography and therefore likely different sources and composition of PM.

Table 3. Change in mean daily RV diastolic pressure (mmHg) per 11.62-µg/m 3 increase in mean PM2.5 concentration on the same day, by level of effect modifier (n = 11 subjects; n = 5,807 person-days).

| Effect modifier | No. of person-days | Change in pressure (mmHg) | 95% CI | Interaction term p-value |
|-----------------|--------------------|---------------------------|-------|-------------------------|
| LVEF (%)        |                    |                           |       |                         |
| ≥ 45            | 1,006              | 0.28                      | 0.05 to 0.51 | 0.61                 |
| < 45            | 4,801              |                           | 0.10 to 0.34 |                      |
| Obesity         |                    |                           |       |                         |
| Obese (BMI ≥ 30)| 3,038              | 0.27                      | 0.14 to 0.40 | 0.22                 |
| Nonobese (BMI < 30) | 1,969       | 0.15                      | -0.02 to 0.32 |                     |
| Access randomization group | | | | |
| Total clinician access | 2,305           | 0.16                      | 0.00 to 0.32 | 0.22                 |
| Blocked clinician access | 3,502        | 0.28                      | 0.14 to 0.41 |                     |
| Season*          |                    |                           |       |                         |
| Winter           | 1,297              | 0.31                      | 0.09 to 0.54 | 0.33                 |
| Summer           | 1,374              | 0.15                      | -0.09 to 0.39 |                     |

*Winter, December–February; Summer, June–August. We excluded person-days occurring in the spring or autumn from this analysis.
Nemery B. 2003. Diesel exhaust particles in lung acutely enhance experimental peripheral thrombosis. Circulation 107:1202–1208.

Nemmar A, Hoyler MS, Hoehn PL, Dinsdale D, Smith T, Hajian X, et al. 2002. Ultrafine particles affect experimental thrombosis in an in vivo hamster model. Am J Respir Crit Care Med 166:998–1004.

Dhillo A, Bennett T, Nordlander R, Rydén J, Aström J, Rydén L. 1995. Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. J Cardiac Fail 1:161–168.

O’Neill MS, Veves A, Sarnat JA, Zanobetti A, Gold DR, Ohlsson A, Bennett T, Nordlander R, Rydén J, Astrom J, Rydén L. 2001. Increased risk of cardiac arrhythmias detected by implantable cardioverter defibrillators in patients with implantable cardioverter defibrillators. In: Inhal Toxicol 16:363–372.

Rich KE, Petkau J, Vedal S, Brauer M. 2004. A case-crossover analysis of particulate air pollution and cardiac arrhythmia in patients with implantable cardioverter defibrillators. Inhal Toxicol 18:123–132.

Rich DQ, Schwartz J, Mittleman MA, Luttmann-Gibson H, Link M, Catalano PJ, et al. 2005. Association of particulate air pollution and ICD-detected ventricular arrhythmias in Boston, MA. Am J Epidemiol 161:1123–1132.

Economides PA, et al. 2007. Air pollution and markers of inflammation on type 2 diabetes: a mechanism for susceptibility. Occup Environ Med 64:373–379.

Steadman RG. 1979. The assessment of sultriness. Part II: Effects of wind, extra radiation and barometric pressure on apparent temperature. J Appl Meteorol 18:874–885.

Sullivan J, Sheppard L, Schreuder A, Ishikawa N, Siscovick D, Kaufman J. 2005. Relation between short-term fine-particulate matter exposure and onset of myocardial infarction. Epidemiology 16(1):41–48.

Simmons JM, Wang L, Guaspari E, Howell E, Dominici F, Schwab M, et al. 2006. A case-crossover study of fine particulate matter air pollution and onset of congestive heart failure symptom exacerbation leading to hospitalization. Am J Epidemiol 164(5):434–436.

Rich DQ, Schwartz JD, Mittleman MA, Link MS, Luttmann-Gibson H, Catalano PJ, et al. 2006b. Increased risk of paroxysmal atrial fibrillation episodes associated with acute increases in ambient air pollution. Environ Health Perspect 114:120–123.

Wellenius GA, Catalano PJ, et al. 2007. Persistent endothelial dysfunction in humans after diesel exhaust inhalation. Am J Respir Crit Care Med 176(4):395–400.

U.S. EPA. 2007. Technology Transfer Network—Air Quality System (AQS) Data Mart. Washington, DC: U.S. Environmental Protection Agency. Available: http://www.epa.gov/ttn/airs/aqsdatamart/access/interface.htm [accessed 15 December 2007].

Wellenius GA, Schwartz J. 2005a. Particulate air pollution and the rate of hospitalization for congestive heart failure among Medicare beneficiaries in Pittsburgh, Pennsylvania. Am J Epidemiol 161:130–136.

Wellenius GA, Coull BA, Godleski JJ, Kourakis P, Okabe K, Salvage ST, et al. 2003. Inhalation of concentrated ambient air particles exacerbates myocardial ischemia in conscious dogs. Environ Health Perspect 111:402–408.

Wellenius GA, Schwartz J, Mittleman MA. 2006b. Air pollution and hospital admissions for ischemic and hemorrhagic stroke among Medicare beneficiaries. Stroke 36:2549–2553.

Symons JM, Wang L, Guaspari E, Howell E, Dominici F, Schwab M, et al. 2008. A case-crossover study of fine particulate matter air pollution and the rate of hospitalization for myocardial infarction. Environ Health Perspect 116:933–937.

Zeka A, Sullivan JR, Vokonas PS, Sparrow D, Schwartz J. 2006. Inflammatory markers and particulate air pollution: characterizing the pathway to disease. Int J Epidemiol 35(5):1347–1354.

Zile MR, Brutsaert DL. 2002. New concepts in diastolic dysfunction and diastolic heart failure. Part II: Causal mechanisms and treatment. Circulation 105:1503–1508.